Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations

Leuk Lymphoma. 2016 Sep;57(9):2235-8. doi: 10.3109/10428194.2015.1135433. Epub 2016 Jan 12.

Authors

Marius Stiefelhagen¹, Carola Gigel¹, Elena Vasyutina¹, Michael Möllmann², Alexandra Breuer¹, Petra Mayer¹, Jan Dürig², Marco Herling¹

Affiliations

¹ a Department of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD) , University of Cologne , Germany ;
² b Clinic of Hematology, University Hospital of Essen , Germany.

PMID: 26758550
DOI: 10.3109/10428194.2015.1135433

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
CD40 Antigens
Heterografts*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Vidarabine* / analogs & derivatives

Substances

Antibodies, Monoclonal, Humanized
CD40 Antigens
Vidarabine
lucatumumab
fludarabine